Major pharmaceutical companies are acquiring biotech firms at a record rate, driven by an urgent need to replenish drug pipelines as lucrative patents expire.
The surge in deal-making reflects a strategic shift among big pharma groups, which are using windfalls from existing blockbuster medicines to secure the next generation of high-value therapies.
Global mergers and acquisitions are on track to reach $4 trillion in deal value this year, marking the most active period for corporate consolidation since 2021.
This activity is also being facilitated by a regulatory environment that has become more accommodating to mergers and acquisitions.
The acceleration in biotech consolidation is part of a wider macroeconomic trend.
Global mergers and acquisitions are on track to reach $4 trillion in deal value this year, marking the most active period for corporate consolidation since 2021.
While industrial sectors have seen record activity driven by artificial intelligence infrastructure and reshoring efforts, the healthcare sector is now mirroring this intensity as companies seek to secure capacity and intellectual property in a competitive landscape.